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cate that there was no delay in the diagnosis of AKI. By
comparison, ﬁgures reported in a multicenter study per-
formed in several North American hospitals were 48% for
stage 1 and 23% for stage 3 [3]. Moreover, in our study,
progression from stages 1 and 2 to higher stages
occurred in only 22% of patients, a ﬁgure much lower
than the 44% reported in the former study [3]. Therefore,
it appears as though that the use of a 1.5 mg/dl cut-off,
to identify patients with greater kidney dysfunction and
worse prognosis, neither delayed the diagnosis of AKI
nor resulted in a higher rate of progression, compared
to other published reports.
(4) Finally, recent studies from the EASL-CLIF Consortium
highlight the importance of considering, not only kidney
failure, but also the potential co-existence of other organ
failures in patients hospitalized for acute decompensation
of cirrhosis [4]. In this regard, a recent study has shown
that the use of the ACLF classiﬁcation has a higher
predictive accuracy than the AKI classiﬁcation in predict-
ing 28-day and 90-day mortality in cirrhosis [5]. There-
fore, these results suggest that the ACLF classiﬁcation
should be used in patients with cirrhosis hospitalized
for acute decompensation to assess prognosis and also
guide speciﬁc therapies aimed at improving function of
multiple organs.
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Reply to: ‘‘A cut-off serum creatinine value of 1.5 mg/dl
for AKI – To be or not to be’’
A cut-off creatinine value of 1.5 mg/dl for AKI: sometimes ‘‘the
question’’ does not concern ‘‘the being’’, but ‘‘the meaning’’
To the Editor:
We want to thank Wong et al. for their interest in our study pub-
lished in 2013 in the Journal of Hepatology regarding the applica-
tion of acute kidney injury network (AKIN) criteria in the
diagnosis of acute kidney injury (AKI) in patients with cirrhosis
and ascites [1]. In their letter Wong et al. express their concern
about the use of a cut off serum creatinine (sCr) of 1.5 mg/dl in
the diagnosis of AKI in patients with cirrhosis, in particular in wo-
men. They reported that in hospitalized patients with cirrhosis
and bacterial infections, patients with AKI and a peak sCr
<1.5 mg/dl had a poor survival than patients without AKI. These
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Open access under CC BY-NC-ND license.results are interesting and emphasize that in the setting of bacte-
rial infections mild impairment of renal function may be associ-
ated with poor short-term outcome. However, let us summarize
the development of the application of AKI criteria in patients with
cirrhosis. After the appearance of the AKIN criteria, a working
party of specialists from multiple disciplines proposed summary
statements for the classiﬁcation of renal dysfunction in cirrhosis,
including the AKIN classiﬁcation [2]. However, as hepatologists,
we have used for several years our own deﬁnition of acute renal
failure, achieving relevant results in its prevention and treatment
[3]. Thus, the International Club of Ascites proposed to compare
our own diagnostic criteria of acute renal failure with the AKIN
criteria in terms of prognostic accuracy, rather than to accept
uncritically the latter [4]. Thus, our prospective clinical study
was speciﬁcally aimed to address this relevant issue. Now, let us
to explain better the main observations reported in our
manuscript, since it appears they have been misunderstood. First015 vol. 62 j 739–752
of all we want to highlight that we have never suggested
maintaining the cut-off sCr of 1.5 mg/dl for the diagnosis of AKI
in patients with cirrhosis. We clearly stated that the AKIN criteria
and the AKIN staging of AKI should be accepted and used in pa-
tients with cirrhosis. Then, we suggested using two parameters,
namely a cut-off sCr of 1.5 mg/dl and/or AKI stage progression,
in order to titrate the intensity of treatment in patients with initial
AKI stage 1. In fact, our data showed that, in this subgroup of pa-
tients, a sCr <1.5 mg/dl was able to predict both an low probability
of AKI progression (<10%) to a higher stage and a high probability
of AKI resolution (>70%) by simple therapeutic measures that we
will mention later on. Conversely, in patients with an initial AKI
stage 1, a value of sCr P1.5 mg/dl was found to be a predictor
of both progression of the AKI stage and poor in hospital survival
[1]. Fagundes et al. reported similar results in the same issue of the
Journal [5]. According to these data, Fagundes et al. proposed a
new classiﬁcation of AKI dividing patients with peak stage 1 AKI
in 2 groups according to sCr >or 61.5 mg/dl [5]. Moving to the
management of AKI stage 1 and sCr <1.5 mg/dl, nowhere in our
paper is reported that AKI stage 1 with sCr <1.5 mg/dl should be
considered a benign condition. In fact, speciﬁc interventions were
suggested for these patients, namely withdrawal of nephrotoxic
drugs, tapering or withdrawal of diuretics, treatment of bacterial
infections and plasma volume expansion, according to clinical
scenario. Thesemeasures are similar to those suggested by Kidney
Disease Improving Global Outcome (KDIGO) practice guidelines
for the management of AKI in the general population [6] and they
were applied both in our study and in Fagundes’ study. These
treatments led to resolution of AKI in 70.6% of patients with AKI
stage 1 and serum creatinine <1.5 mg/dl [1]. Finally, we proposed
a close follow up of these patients in spite of the resolution of AKI
just relying this recommendation on the data of Tsien et al. [7]. We
do not think that we have underestimated this clinical condition.
Moving now to patients with initial AKI stagewith sCrP1.5 mg/dl
and/or progression of AKI stage, we suggested applying the same
intensive treatment provided for patients with initial AKI stage 2
or 3. This treatment includes plasma volume expansion with the
maximal provided doses of albumin (i.e., 1 g/kg of body weight
for two consecutive days) and, in case of fulﬁllment of all the other
diagnostic criteria for hepatorenal syndrome (HRS), vasoconstric-
tors plus albumin. Thus, deﬁnitively, we proposed to maintain a
sCr cut off value of 1.5 mg/dl mainly in order to avoid a risky
and unjustiﬁed use of vasoconstrictors, and in particular of terli-
pressin in patients with AKI-HRS stage 1 without progression.
To be clearer we propose two brief questions about two clinical
cases of cirrhosis with AKI stage 1 without progression, that is
peak AKI stage 1. Would you treat with vasoconstrictors and albu-
min a patient with a value of sCr going up from 0.6 to 1.0 mg/dl
(AKI stage 1with sCr <1.5 mg/dl) who fulﬁlls all the other diagnos-
tic criteria for AKI-HRS? Would you treat with vasoconstrictors
and albumin a patient with a value of sCr going up from 1.3 to
1.7 mg/dl (AKI stage 1 with sCr P1.5 mg/dl) who fulﬁlls all the
other diagnostic criteria for AKI-HRS? We think that there is no
need to hire the Gallup pool to state that most of the experts
would answer no to the ﬁrst and yes to the second question.
Why? Because only in the second case the impairment of renal
function would be considered large enough to justify in terms of
risk/beneﬁt the treatment with vasoconstrictors and albumin. In
order to complete the discussion, please note that in patients with
initial AKI stage 2 and 3, no cut-off was provided for the manage-
ment of AKI in our algorithm, giving the possibility to treat inten-
sively a patient with baseline sCr level of 0.6 mg/dl who develops
AKI with an initial sCr even below 1.5 mg/dl (e.g. 1.3 mg/dl) be-
cause we proved he/she, having an initial AKI stage 2, has a high
risk of short term mortality. In this regard it would be interesting
to know how many patients with AKI and sCr <1.5 mg/dl had AKI
stage 1 and how many had AKI stage >1 in the cohort of Wong
et al., since these data were not reported. Thus, in our view, the
use of the threshold sCr of 1.5 mg/dl is not detrimental. Neverthe-
less, as we stated in the manuscript, our algorithm is a simple
working hypothesis, and we are fully agree with Wong et al. that
large prospective controlled interventional studies are needed to
clarify this issue.
As far as a possible discrimination against women is con-
cerned, we fully agree that the assessment of glomerular ﬁltration
rate (GFR) with sCr is a relevant problem in female, both in the
general population and in those with cirrhosis. However, this is
a limitation of the use of sCr as a marker of GFRmore than of AKIN
criteria. Furthermore these limits are shared with all the scores in
which sCr is included, such as MELD score. In fact, beyond its
amazing merits, the use of MELD score in the assessment of prog-
nosis and in priority allocation for liver transplantation penalizes
females [8]. Furthermore, in the calculation of MELD score all sCr
values below 1 mg/dl are bounded to 1 mg/dl. This is a serious lim-
itation since patients with cirrhosis and sCr below 1 mg/dl may
have wide variations in measured GFR [9]. Thus, this point raised
by Wong et al. looks a little bit like what we deﬁne, in soccer, an
own goal. Thus, joke aside, we would like to invite the authors
to direct the value of their observation on discrimination against
women also to the liver transplant setting, where it is probably
more relevant that in the management of AKI. We would be very
interested to investigate these issues in collaborative prospective
studies.
The last point raised by Wong et al., is the prognostic im-
pact of failure of organs other than the kidney in patients with
cirrhosis. Wong et al. seem to suggest that AKI has a deeper
negative impact on prognosis than other organ failures. There
is no doubt about the negative effect of renal failure on prog-
nosis of patients with cirrhosis and bacterial infections. As hep-
atologists, we know it from several years [10,11]. Nevertheless,
it has recently been shown that a classiﬁcation based on the
acute-on-chronic liver failure (ACLF) stages, which was recently
proposed by the Canonic study [12], has a higher accuracy than
that based on AKI stages in the prediction of short term mor-
tality in patients who were admitted to the hospital for an
acute decompensation of cirrhosis [13]. These data suggest that
the prognostic evaluation of patients with an acute decompen-
sation of cirrhosis cannot ignore the failures of organs other
than the kidney.
Once we have clariﬁed all of this, we share the conclusions
of Wong et al. that prospective clinical trials are needed on
several steps of the management of AKI in patients with cirrho-
sis considering all the possible clinical scenarios. We also agree
that we should work together to achieve shared criteria in the
management of AKI in cirrhosis. Wong et al. well know we are
already doing it all together, because we all strongly believe
that, in science, the different opinions should always create
an opportunity for a worldwide growth of knowledge and
never a reason for disputes or for something even worse, that
is a harmful division in the scientiﬁc community.
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Interaction between infection and hepatic encephalopathy
To the Editor:
We read with interest ‘‘The Hepatic Encephalopathy Practice
Guidelines’’ published in the September issue of the Journal of
Hepatology [1].
As underlined by the authors in Table 3, infections are
extremely frequent as precipitating factors for overt hepatic
encephalopathy (OHE). In our tertiary referral centre, with
an ongoing project for the search of active infection at
hospital admission, infection was the precipitating event
in 56% of patients with OHE in a study performed in
2008 and 2009 [2]. This prevalence has increased to 64%
in 2012 (personal data).
In the same article however, the authors claim that ‘‘patients
with cirrhosis do not differ from patients without cirrhosis
regarding their risk to develop brain dysfunction with sepsis’’.
We disagree with this information. We have recently investigated
the association between bacterial infections and cognitive
dysfunction in 150 cirrhotic patients and 81 non-cirrhotic con-
trols [3]. Signs of neurocognitive impairment were systematically
looked for by means of standardized clinical examination or by
the application of psychometric tests in both groups. Following
a diagnosis of sepsis, neurocognitive alterations were signiﬁ-
cantly more frequent in cirrhotic patients than in controls (90%
vs. 39% cirrhotic patients vs. non-cirrhotic controls). In cirrhotic
patients, the probability to ﬁnd neurocognitive alterations
increased from patients without infection (42%) to patients with
infection and no systemic inﬂammatory response syndrome
(SIRS) (79%) to those with sepsis (90%). Efﬁcaciously treated
patients, in whom the infection subsided, improved their neuro-
logical symptoms. Both overt and covert hepatic encephalopathy
were inﬂuenced by the presence of infection and by its
resolution.
These results are in keeping with a role for inﬂammation in
the pathogenesis of HE [4]. Other authors have supported this
hypothesis: the administration of LPS has been found to alter
consciousness and to exacerbate brain oedema only in rats with
liver damage [5]; and ibuprofen restored the learning ability of
rats with portacaval shunts and cognitive impairment [6]. In
cirrhotic patients, serum levels of TNF-alfa [7], as well as of IL-6
and IL-18 [8,9] were associated with the presence and severity
of overt and minimal HE. Indeed pro-inﬂammatory cytokines
may contribute to HE in cirrhotic patients by acting synergically
with hyperammonemia [10]. Interestingly, in our study [3] the
mean ammonia plasma levels associated with OHE were lower
in patients with concomitant infection/inﬂammation than in
those without infection.
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